Company performance
Add to research
Current Price
as of Jul 11, 2025$37.09
P/E Ratio
151.99
Market Cap
$5.89B
Description
Add to research
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.
Metrics
Add to research
Overview
- HQMorrisville, NC
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerTGTX
- Price$37.085-1.55%
Trading Information
- Market cap$5.89B
- Float90.00%
- Average Daily Volume (1m)1,562,235
- Average Daily Volume (3m)2,162,422
- EPS$0.27
Company
- Revenue$386.39M
- Rev growth (1yr)90.40%
- Net income$5.06M
- Gross margin87.09%
- EBITDA margin7.18%
- EBITDA$8.68M
- EV$6.40B
- EV/Revenue16.55
- P/E151.99
- P/S15.62
- P/B24.72
- Debt/Equity106.92
Documents
Add to research
SEC Filings
Earnings Calls